source
- FDA approves Roivant's oral dermatomyositis drug Lisraya (brepocitinib)The U.S. Food and Drug Administration has granted approval to Roivant's drug brepocitinib, which will be sold under the brand name Lisraya. The decision marks the first major regulatory clearance f…
- Scaling delivery is key for CAR T therapies to succeed in autoimmune diseasesBiopharma companies are exploring CAR T cell therapies as a potential cure for autoimmune disorders, a market that could be twice the size of oncology. While current treatments manage symptoms, the…